STOCK TITAN

Impact Biomedical closes merger; 8.64M shares for common holders

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Impact Biomedical Inc. (IBO) completed a business combination on November 17, 2026: Merger Sub merged into IBO, which continues as a wholly-owned subsidiary of PubCo, and PubCo acquired all outstanding shares of Zoar. Zoar’s sole shareholder received 167,976,000 PubCo ordinary shares, approximately 94.02% of PubCo at closing. Former IBO common stockholders became entitled to 8,640,000 PubCo ordinary shares, approximately 4.80% of shares outstanding at closing; PubCo paid no cash consideration.

Before the merger’s effective time, IBO common stock underwent a 1-for-12.62 reverse split. IBO’s directors, CFO and COO resigned; Kanans Visvanats became PubCo’s CEO and interim CFO. PubCo also issued 22,000 compensation shares to IBO CEO Frank D. Heuszel. IBO requested suspension and delisting of its common stock from NYSE American; delisting will be effective ten days after Form 25 is filed. PubCo shares are expected to begin trading as ZOAR on November 18, 2026.

1 point · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Major pointPubCo completed the Zoar acquisition, issuing 167,976,000 ordinary shares.

Negative

  • None.

Filing Explained

At closing, unvested IBO options and warrants became exercisable; in-the-money instruments were canceled for net IBO shares, after tax withholding, that converted into PubCo-share rights, while instruments priced at or above the closing price were canceled for no consideration.

Item 2.01 Completion of Acquisition or Disposition of Assets Financial
The company completed a significant acquisition or sale of business assets.
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities
The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.
Item 3.03 Material Modification to Rights of Security Holders Securities
A change was made that materially affects the rights of existing shareholders (e.g., dividend rights, voting rights).
Item 5.01 Changes in Control of Registrant Governance
A change in control of the company occurred, such as through a merger, takeover, or management buyout.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Merger consideration to former IBO common stockholders 8,640,000 PubCo ordinary shares Aggregate shares stockholders became entitled to receive; approximately 4.80% of PubCo’s total issued and outstanding ordinary shares at closing.
Former IBO stockholders’ share of PubCo Approximately 4.80% Share of total issued and outstanding PubCo ordinary shares at closing.
Shares issued to Zoar’s sole shareholder 167,976,000 PubCo ordinary shares Approximately 94.02% of total issued and outstanding PubCo ordinary shares at closing.
Zoar shareholder’s PubCo ownership Approximately 94.02% Ownership immediately following the business combination.
Compensation shares issued to Frank D. Heuszel 22,000 PubCo ordinary shares Issued to IBO’s Chief Executive Officer at closing.
NYSE Reverse Split 1-for-12.62 IBO common stock reverse split effected before the merger’s effective time.
Merger Consideration technical
"the “Merger Consideration”"
Merger consideration is the total payment a company or buyer offers to shareholders of a target company in exchange for combining the two businesses, and can include cash, shares in the surviving company, debt assumption, or a mix of these. Investors care because the form and amount affect the deal’s value, tax consequences, immediate cash received versus future ownership, and the risk and upside of holding new shares — similar to choosing between cash now or stock that could grow later.
In the Money Impact Options technical
"each In the Money Impact Option and In the Money Impact Warrant"
Effective Time technical
"The Merger became effective upon the filing of the Articles of Merger"
The exact clock time when a regulatory filing, approval, or corporate action formally becomes legally active; from that moment the change is binding and can be acted on. Investors care because the effective time marks when ownership, rights, trading rules, or new securities take effect — like a light switch turning on a contract or transaction — which determines when risks, benefits and market reactions begin.
Form 25 regulatory
"a notification of removal from listing on Form 25"
A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What happened to IBO in the November 2026 business combination?

IBO became a wholly-owned subsidiary of PubCo after Merger Sub merged into it, and PubCo acquired all outstanding shares of Zoar from its sole shareholder. The transactions closed on November 17, 2026.

How many PubCo shares did former IBO shareholders receive?

Former IBO common stockholders became entitled to 8,640,000 PubCo ordinary shares, approximately 4.80% of PubCo’s total issued and outstanding ordinary shares at closing. PubCo paid no cash consideration.

Who controls PubCo after the IBO business combination?

Kanans Visvanats holds approximately 94.02% of PubCo’s issued and outstanding ordinary shares and therefore controls a majority of its voting power and indirectly controls IBO. He was appointed PubCo’s CEO and interim CFO.

What happens to the IBO listing, and what is PubCo’s ticker?

IBO requested suspension and removal of its common stock from NYSE American; delisting will be effective ten days after Form 25 is filed. PubCo ordinary shares are expected to trade as ZOAR on November 18, 2026 on NYSE American.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false --12-31 0001834105 0001834105 2026-11-17 2026-11-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 17, 2026

 

IMPACT BIOMEDICAL INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-42212   85-3926944

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

275 Wiregrass Pkwy, West Henrietta, New York   14586
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (585) 232-1500

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Ticker symbol(s)   Name of each exchange on which registered
Common Stock, $0.001 par value per share   IBO   The NYSE American LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Introductory Note.

 

This Current Report on Form 8-K is being filed in connection with the completion of the transactions contemplated by the previously announced Merger and Share Exchange Agreement, dated as of June 21, 2025, by and among Impact BioMedical Inc., a Nevada corporation (the “Company” or “Impact”), Zoar Limited (formerly known as Dr Ashleys Limited), a Cayman Islands exempted company limited by shares (“PubCo”), Dr Ashleys Nevada Sub, Inc., a Nevada corporation and a wholly-owned subsidiary of PubCo (“Merger Sub”), Zoar Labs Limited (formerly known as Dr Ashleys Bio Labs Limited), a Cayman Islands exempted company limited by shares (“Zoar”), and Kanans Visvanats (a.k.a. Kannan Vishwanatth), solely in his capacity as the sole shareholder of Zoar (the “Zoar Shareholder”) (the “Original Agreement”), as amended by the Amended and Restated Amendment to the Merger and Share Exchange Agreement, dated as of June 30, 2026 (which rescinded and superseded an amendment dated February 27, 2026), and the Second Amended and Restated Amendment to the Merger and Share Exchange Agreement, dated as of August 13, 2026 (the Original Agreement, as so amended, the “Merger Agreement”).

 

Item 2.01. Completion of Acquisition or Disposition of Assets.

 

Pursuant to the Merger Agreement, on November 17, 2026 (the “Closing Date”), (i) Merger Sub merged with and into the Company (the “Merger”), with the Company continuing as the surviving corporation and as a wholly-owned subsidiary of PubCo (the “Surviving Corporation”), and (ii) simultaneously with or immediately following the Merger, PubCo acquired from the Zoar Shareholder all of the issued and outstanding ordinary shares of Zoar, as a result of which Zoar became a wholly-owned subsidiary of PubCo (the “Share Exchange” and, together with the Merger and the other transactions contemplated by the Merger Agreement, the “Business Combination”). The Merger became effective upon the filing of the Articles of Merger with the Secretary of State of the State of Nevada on the Closing Date (the “Effective Time”).

 

As previously reported, the Business Combination and the Merger Agreement were adopted and approved by the Company’s stockholders at the special meeting of stockholders held on November 13, 2026.

 

Pursuant to the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of any party or the holders of any securities of the Company or PubCo, (i) each share of common stock, par value $0.001 per share, of the Company (the “Company Common Stock”), after giving effect to a reverse stock split of the Company Common Stock effected prior to the Effective Time at a ratio of 1-for 12.62- (the “NYSE Reverse Split”), issued and outstanding immediately prior to the Effective Time was converted into the right to receive one ordinary share of PubCo (each, a “PubCo Ordinary Share”), such that the holders of Company Common Stock received, in the aggregate, 8,640,000 PubCo Ordinary Shares, representing approximately 4.80% of the total issued and outstanding PubCo Ordinary Shares at the Closing (the “Merger Consideration”), and (ii) each share of common stock of Merger Sub issued and outstanding immediately prior to the Effective Time was converted into one validly issued, fully paid and non-assessable share of common stock of the Surviving Corporation. The shares of Company Common Stock entitled to receive the Merger Consideration included shares issued upon the exercise or settlement of In the Money Impact Options and In the Money Impact Warrants (each as defined in the Merger Agreement), if any.

 

Page 2
 

 

At the Effective Time, (i) each outstanding option to purchase Company Common Stock (each, an “Impact Option”) and each outstanding warrant to purchase Company Common Stock (each, an “Impact Warrant”) that was not then vested or exercisable became vested and exercisable in full immediately prior to the Effective Time, (ii) each In the Money Impact Option and In the Money Impact Warrant was cancelled, and its holder became entitled to receive, immediately prior to the Effective Time, a number of shares of Company Common Stock equal to the number of shares underlying such Impact Option or Impact Warrant, less shares withheld to satisfy applicable tax withholding obligations, which shares were converted into the right to receive the Merger Consideration, and (iii) each Impact Option and Impact Warrant with an exercise price equal to or greater than the Impact Closing Price (as defined in the Merger Agreement) was cancelled for no consideration.

 

In connection with the Share Exchange, PubCo issued at the Closing (i) 167,976,000 PubCo Ordinary Shares to the Zoar Shareholder, representing approximately 94.02% of the total issued and outstanding PubCo Ordinary Shares at the Closing, (ii) 22,000 PubCo Ordinary Shares to Frank D. Heuszel, the Company’s Chief Executive Officer (the “Compensation Shares”), (iii) 228,000 PubCo Ordinary Shares to DSS, Inc. (the “DSS Shares”), and (iv) 1,800,000 PubCo Ordinary Shares to BMI Capital International LLC, representing approximately 1.00% of the total issued and outstanding PubCo Ordinary Shares at the Closing.

 

The PubCo Ordinary Shares issued in the Business Combination were registered under the Securities Act of 1933, as amended (the “Securities Act”), under PubCo’s Registration Statement on Form F-4 (File No. 333-298856), which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on October 23, 2026. The PubCo Ordinary Shares are expected to begin trading on the NYSE American LLC (“NYSE American”) under the symbol “ZOAR” on November 18, 2026.

 

The foregoing description of the Merger, the Business Combination and the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Merger Agreement, copies of which are filed as Exhibits 2.1, 2.2 and 2.3 to this Current Report on Form 8-K and are incorporated by reference into this Item 2.01.

 

The information set forth in the Introductory Note of this Current Report on Form 8-K is incorporated by reference into this Item 2.01.

 

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

On the Closing Date, the Company notified NYSE American that the Merger had been completed and requested that NYSE American (i) suspend trading of the Company Common Stock prior to the open of trading on November 18, 2026, (ii) withdraw the Company’s Common Stock from listing on NYSE American, and (iii) file with the SEC a notification of removal from listing on Form 25 to delist the Company Common Stock from NYSE American and deregister the Company Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). As a result, the Company Common Stock, which previously traded under the symbol “IBO,” will no longer be listed on NYSE American. The delisting will be effective ten (10) days after the Form 25 is filed.

 

Additionally, after the Form 25 becomes effective, the Company intends to file with the SEC a certification on Form 15 under the Exchange Act requesting the deregistration of the Company Common Stock under Section 12(g) of the Exchange Act and the suspension of the Company’s reporting obligations under Sections 13 and 15(d) of the Exchange Act.

 

The information set forth in the Introductory Note and under Item 2.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.01.

 

Page 3
 

 

Item 3.03. Material Modification to Rights of Security Holders.

 

At the Effective Time, each issued and outstanding share of Company Common Stock (after giving effect to the NYSE Reverse Split) was cancelled and converted into the right to receive the Merger Consideration, and each Impact Option and Impact Warrant was treated as described in Item 2.01. Accordingly, at the Effective Time, holders of Company Common Stock ceased to have any rights as stockholders of the Company, other than the right to receive the Merger Consideration. Holders of PubCo Ordinary Shares hold the rights provided under PubCo’s amended and restated memorandum and articles of association, which became effective simultaneously with or immediately following the Share Exchange, and under the laws of the Cayman Islands.

 

The information set forth in the Introductory Note and under Items 2.01, 3.01, 5.01 and 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03.

 

Item 5.01. Changes in Control of Registrant.

 

At the Effective Time, Merger Sub merged with and into the Company pursuant to the Merger Agreement. The Company continued as the surviving corporation and became a wholly-owned subsidiary of PubCo. As a result, a change in control of the Company occurred. PubCo funded the Merger Consideration through the issuance of PubCo Ordinary Shares and paid no cash consideration. Immediately following the Business Combination, the Zoar Shareholder, Kanans Visvanats, holds approximately 94.02% of the issued and outstanding PubCo Ordinary Shares and therefore controls a majority of the voting power of PubCo, and indirectly of the Company.

 

The information set forth in the Introductory Note and under Items 2.01, 3.01, 3.03 and 5.02 of this Current Report on Form 8-K is incorporated by reference into this Item 5.01.

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Pursuant to Section 2.5 of the Merger Agreement, at the Effective Time, each member of the Company’s board of directors, the Chief Financial Officer, and the Chief Operating Officer resigned and ceased to hold office.

 

Also pursuant to Section 2.5 of the Merger Agreement, at the Effective Time, the following were appointed as directors of the Board of Directors of PubCo, the Company’s parent: Kanans Visvanats (Chairman), Donald Kalkofen, Michael Zajas, Evan Lim, Neha Kumari, Maduabuchi Nelson Okey, Bang-Ning (Simon) Liu and David A. Sanders. The executive officers of PubCo are Kanans Visvanats (Chief Executive Officer and Interim Chief Financial Officer), Adrian Anthony Simon Markland (Chief Operating Officer) and Sameer Ramesh Talim (Head of Sales and Marketing). Each will hold office in accordance until his or her resignation or removal or until a successor is duly elected or appointed and qualified.

 

Pursuant to Section 3.2(d) of the Merger Agreement, as amended, PubCo issued the 22,000 Compensation Shares to Mr. Heuszel at the Closing. The Compensation Shares were registered under the Registration Statement on Form F-4.

 

Page 4
 

 

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

Pursuant to Section 2.4 of the Merger Agreement, at the Effective Time, the articles of incorporation and bylaws of the Company, as in effect immediately prior to the Effective Time, were amended and restated in their entirety to read in the form of the articles of incorporation and bylaws of Merger Sub as in effect immediately prior to the Effective Time, except that (i) the name of the Surviving Corporation was changed to “Dr Ashleys USA Inc.”, (ii) the NYSE Reverse Split was effected, and (iii) PubCo made such other changes as it deemed appropriate. The Company previously announced and disclosed the NYSE Reverse Split on a Current Report on Form 8-K filed with the SEC on October 9, 2026, and is incorporated herein by reference.

 

The information set forth in Item 2.01 is incorporated by reference into this Item 5.03.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description of Exhibit
2.1   Merger and Share Exchange Agreement, dated as of June 21, 2025, by and among Dr Ashleys Limited, Impact BioMedical Inc., Dr Ashleys Nevada Sub, Inc., Dr Ashleys Bio Labs Limited and Kanans Visvanats (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed on June 23, 2025).
2.2   Amended and Restated Amendment to the Merger and Share Exchange Agreement, dated as of June 30, 2026.
2.3   Second Amended and Restated Amendment to the Merger and Share Exchange Agreement, dated as of August 13, 2026.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

Page 5
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

 

  IMPACT BIOMEDICAL INC.
     
Date: November 18, 2026 By: /s/ Frank D. Heuszel
  Name: Frank D. Heuszel
  Title: Chief Executive Officer

 

Page 6

 

Filing Exhibits & Attachments

5 documents

Keep reading